Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614505 | 1.00 | MC4R (0.55) | MC4RACEPPARAPPARGTP53 | |
| SCHEMBL29726536 | 1.00 | MC4R (0.55) | MC4RACEPPARAPPARGTP53 | |
| SCHEMBL1749008 | 1.00 | MC4R (0.55) | MC4RACEPPARAPPARGTP53 | |
| SCHEMBL23357004 | 0.89 | ACE (0.51) | MC4RACEPPARAPPARGCTSL | |
| SCHEMBL2796961 | 0.89 | PPARA (0.51) | MC4RACEPPARAPPARGTP53 | |
| SCHEMBL23357002 | 0.89 | ACE (0.51) | MC4RACEPPARAPPARGCTSL | |
| SCHEMBL12737917 | 0.89 | PPARA (0.51) | MC4RACEPPARAPPARGTP53 | |
| SCHEMBL5319509 | 0.88 | ACE (0.50) | MC4RACEPPARAPPARGCTSL | |
| SCHEMBL5321402 | 0.88 | CTSS (0.53) | MC4RACEPPARAPPARGTP53 | |
| SCHEMBL12737973 | 0.88 | CTSS (0.53) | MC4RACEPPARAPPARGTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| US-20240049709-A1 | METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION, (A.R.O), THE VOLCANI INSTITUTE (IL) | 2024-02-15 | — | — | US | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| WO-2022178544-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE IN HDAC INHIBITION | KLOTHO THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-108752241-B | Acylguanidines for the treatment of arthrosis | 默克专利股份公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200383327-A1 | METHOD OF IMPROVING PLANT PERFORMANCE | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2020-12-10 | — | — | US | disclosed |
| CN-105102424-B | Acylguanidines for the treatment of arthrosis | 默克专利股份公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20190246639-A1 | METHOD OF CONTROLLING FUNGAL INFECTIONS IN PLANTS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCHORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2019-08-15 | — | — | US | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9884814-B2 | Acylguanidines for treating osteoarthritis | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1799222-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006030323-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2006-03-23 | — | — | WO | disclosed |
| US-20040192676-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004058735-A2 | LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | MC4R 3949/4885ACE 128/4885PPARA 4407/4885 |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | MC4R 1782/4885ACE 381/4885PPARA 1625/4885 |
| US-20040192676-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC2R | MC4R 5/4885ACE 3595/4885PPARA 1876/4885 |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | MC4R 2218/4885ACE 2157/4885PPARA 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.